Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | CCR1 | P32246 | 3/20 | 0.54 |
| ▸ | CCR5 | P51681 | 3/20 | 0.54 |
| ▸ | CCR8 | P51685 | 3/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | METAP1 | P53582 | 1/20 | 0.54 |
| ▸ | BLM | P54132 | 1/20 | 0.54 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.54 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.54 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 6/20 | 0.52 |
| ▸ | TP53 | P04637 | 4/20 | 0.52 |
| ▸ | RAB9A | P51151 | 4/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1526798 | 0.98 | KDM4E (0.56) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL28463055 | 0.96 | KDM4E (0.54) | KDM4ELMNACCR1CCR5CCR8 | |
| Acetic Acid SCHEMBL28642244 | 0.85 | KDM4E (0.44) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL30440591 | 0.84 | KDM4E (0.62) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL3659891 | 0.84 | KDM4E (0.62) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL4667108 | 0.83 | KDM4E (0.45) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL31055535 | 0.82 | KDM4E (0.41) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL11910164 | 0.75 | KDM4E (0.81) | KDM4ELMNACCR1CCR5CCR8 | |
| Dipyridyl SCHEMBL31695013 | 0.75 | KDM4E (0.93) | KDM4ELMNACCR1CCR5CCR8 | |
| Dipyridyl SCHEMBL391569 | 0.75 | KDM4E (0.93) | KDM4ELMNACCR1CCR5CCR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10018625-B2 | Use of female mammal's urine for determination of fetal gender related characteristics | UROBIOLOGICS LLC (US) | 2018-07-10 | — | — | US | claimed |
| EP-2863220-B1 | Reducing/oxidizing activity of maternal urine as indicator of fetal gender related characteristics | UROBIOLOGICS LLC (US) | 2017-09-06 | — | — | EP | claimed |
| US-20150316540-A1 | REDUCING/OXIDIZING ACTIVITY OF MATERNAL URINE AS INDICATOR OF FETAL GENDER RELATED CHARACTERISTICS | UROBIOLOGICS LLC | 2015-11-05 | — | — | US | claimed |
| US-9057720-B2 | Reducing/oxidizing activity of maternal urine as indicator of fetal gender related characteristics | UROBIOLOGICS LLC (US) | 2015-06-16 | — | — | US | claimed |
| EP-2863220-A2 | Reducing/oxidizing activity of maternal urine as indicator of fetal gender related characteristics | Urobiologics LLC (US) | 2015-04-22 | — | — | EP | claimed |
| US-20140302537-A1 | Use of Female Mammal's Urine for Determination of Fetal Gender Related Characteristics | OURNEXTBABY LLC | 2014-10-09 | — | — | US | claimed |
| EP-2619573-A1 | USE OF FEMALE MAMMAL'S URINE FOR DETERMINATION OF FETAL GENDER RELATED CHARACTERISTICS | Urobiologics LLC (US) | 2013-07-31 | — | — | EP | claimed |
| WO-2012036691-A1 | USE OF FEMALE MAMMAL'S URINE FOR DETERMINATION OF FETAL GENDER RELATED CHARACTERISTICS | UROBIOLOGICS LLC (US) | 2012-03-22 | — | — | WO | claimed |
| US-20110230453-A1 | Use of Female Mammal's Urine for Determination of Fetal Gender Related Characteristics | UROBIOLOGICS LLC (US) | 2011-09-22 | — | — | US | claimed |
| EP-2257803-A2 | REDUCING/OXIDIZING ACTIVITY OF MATERNAL URINE AS INDICATOR OF FETAL GENDER RELATED CHARACTERISTICS | Urobiologics LLC (US) | 2010-12-08 | — | — | EP | claimed |
| US-20090233321-A1 | Reducing/Oxidizing Activity of Maternal Urine As Indicator of Fetal Gender Related Characteristics | UROBIOLOGICS LLC (US) | 2009-09-17 | — | — | US | claimed |
| WO-2009114579-A2 | REDUCING/OXIDIZING ACTIVITY OF MATERNAL URINE AS INDICATOR OF FETAL GENDER RELATED CHARACTERISTICS | UROBIOGICS LLC (US) | 2009-09-17 | — | — | WO | claimed |
| US-6177260-B1 | SIMPLE, EFFICIENT METHOD OF ANALYZING THIOL GROUP CONTAINING PROTEINS, GLUTATHIONE, CYSTEINE, FLAVONOIDS, AND VITAMIN E BY CONTACTING IN ACTIVE AND DEACTIVE STATE WITH OXIDANT RESULTING IN CHANGE OF ABSORBANCE SPECTRA AND COMPARING | THE HONG KONG POLYTECHNIC UNIVERSITY (HK) | 2001-01-23 | — | — | US | claimed |
| CN-117310050-B | Screening method of honeysuckle antioxidation quality markers | 中国中医科学院中医药健康产业研究所 | 2024-02-09 | — | — | CN | disclosed |
| CN-117310050-A | Screening method of honeysuckle antioxidation quality markers | 中国中医科学院中医药健康产业研究所 | 2023-12-29 | — | — | CN | disclosed |
| WO-2023068778-A1 | COMPOSITION FOR PREVENTION AND TREATMENT OF FEMALE MENOPAUSAL DISEASES COMPRISING PHYTOGEN AS ACTIVE INGREDIENT | 리누 바이오 헬스 엘티디. | 2023-04-27 | — | — | WO | disclosed |
| US-20050244983-A1 | Method for measuring antioxidant status | THE WESTERN AUSTRALIAN CENTRE FOR PATHOLOGY AND MEDICAL RESEARCH (AU) | 2005-11-03 | — | — | US | disclosed |
| WO-2004034058-A1 | A METHOD FOR MEASURING ANTIOXIDANT STATUS | THE WESTERN AUSTRALIAN CENTRE FOR PATHOLOGY AND MEDICAL RESEARCH (AU) | 2004-04-22 | — | — | WO | disclosed |
| US-6326034-B1 | FROM YEAST OR SALTBUSH; REGULATE GLUCOSE AND LIPID METABOLISM, INSULIN; TREATMENT OF DIABETES, CARDIOVASCULAR DISEASES AND HYPERLIPIDEMIA; NONTOXIC | NATURAL COMPOUNDS LTD (IL) | 2001-12-04 | — | — | US | disclosed |
| WO-2001045701-A1 | NATURAL EXTRACTED AND SYNTHETIC ANTIOXIDANT COMPOSITIONS | NATURAL COMPOUNDS LTD. (IL) | 2001-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230453-A1 | Use of Female Mammal's Urine for Determination of Fetal Gender Related Characteristics | SHBG, PGF, CYP19A1 | KDM4E 4180/4885LMNA 1670/4885CCR1 3491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.